International Myeloma Society 6th Immune Effector Cell Therapies in Multiple Myeloma Workshop 2025
Include: 9 videos + 1 pdf, size: 9.91 GBTarget Audience: hematologists, oncologists treating multiple myeloma
Information:
The 6th Immune Effector Cell Therapies in Multiple Myeloma Workshop is an advanced two-day educational event dedicated to the latest innovations in immune-based treatments for multiple myeloma. This workshop delivers in-depth scientific updates alongside practical, case-driven discussions to help participants optimize clinical outcomes.
What You Will Learn
-
Latest clinical trial data on CAR T-cell therapies targeting BCMA and GPRC5D
-
Advances in bispecific antibodies and T-cell engagers, including teclistamab, elranatamab, talquetamab, and others
-
Strategies to manage toxicities such as cytokine release syndrome, cytopenias, and organ-specific complications
-
Emerging therapies: allogeneic CAR T, CAR-NK cells, dual antigen targeting, and trispecific antibodies
-
Approaches to overcome resistance and enhance treatment response through combination regimens and immune modulation
Event Details
-
Dates: March 28–29, 2025
-
Location: Boston Marriott Long Wharf, Boston, Massachusetts
Who Should Attend
This workshop is ideal for:
-
Hematologists and oncologists treating multiple myeloma
-
Clinical researchers and trial investigators in immune therapy
-
Advanced practice providers and pharmacists involved in immune effector cell therapy care
-
Industry professionals and academic experts interested in translating research into clinical practice
Why Attend
-
Gain comprehensive insights into the latest immune effector cell therapy developments
-
Learn practical management strategies for complex therapy-related toxicities
-
Network with global leaders and peers in the myeloma research community
-
Apply cutting-edge scientific knowledge directly to patient care
Topics:
- IEC2025Program.pdf
SESSION 1 CLINICAL UPDATES ON CAR T CELLS.mp4
SESSION 2 CLINICAL UPDATES ON BISPECIFIC ABS TCE’S.mp4
SESSION 3 PRACTICAL CONSIDERATIONS FOR IMMUNE THERAPY.mp4
SESSION 4 NOVEL APPROACHES IN THE CLINIC.mp4
SESSION 5 MANAGING TOXICITIES OF T CELL ENGAGING THERAPIES.mp4
SESSION 6 CORRELATES OF RESPONSE AND RESISTANCE.mp4
SESSION 7 STRATEGIES TO IMPROVE IMMUNE EFFECTOR CELL THERAPIES.mp4
SESSION 8 KEY QUESTIONS IN IMMUNE THERAPY.mp4
WORKSHOP ON SECONDARY MALIGNANCIES AND NON-RELAPSE MORTALITY.mp4
